---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-012365"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:55:51.096121+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci Q4 net loss $23.5M; initiates IND-enabling for ABS-101; AstraZeneca deal up to $247M

## Summary
- FY23 net loss $110.6M, revenue $5.7M flat YoY; Q4 net loss $23.5M.
- Initiated IND-enabling for ABS-101 (anti-TL1A); IND expected Q1 2025.
- Signed AstraZeneca collaboration for up to $247M in milestones plus royalties.
- Raised $86.4M in common stock offering; cash $97.7M at Dec 31; runway into H1 2027.
- Appointed Sir Menelas Pangalos to Board and co-chair of Scientific Advisory Board.

## SEC filing metadata
- accession: 0001628280-24-012365
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828024012365/0001628280-24-012365-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828024012365/absc-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-012365
- JSON: https://secwatch.observer/filing/0001628280-24-012365.json
- Plain text: https://secwatch.observer/filing/0001628280-24-012365.txt

## Key facts
- Earnings Releases
  Absci Corp reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 21, 2024, Absci Corporation (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672688/000162828024012365/0001628280-24-012365-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.